Hasten Biopharmaceutical
CompanyChina
Hasten Biopharmaceutical develops one asset, approved (lerodalcibep in hypercholesterolemia). Mostly protein or enzyme acting on PCSK9; based in China.
- 1
- Asset
- Furthest stage
- Approved
- 2
- Trials
- 7
- Signals
Pipeline
1Inhibits PCSK9, preserving LDL receptors and increasing clearance of LDL cholesterol from blood.
Approved, Protein or enzyme, PCSK9, hypercholesterolemia, heterozygous familial hypercholesterolemia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Signals13
- Similar companies6